In recent years, the management of systemic amyloidosis has greatly improved due to increased disease awareness, the introduction of accurate diagnostic tools, the development of powerful prognostic and companion biomarkers, and a continuous flow of innovative therapies, which has resulted into the blooming of phase 2/3 interventional studies for both light chain (AL) and transthyretin (ATTR) amyloidosis [1,2,3]. The gene discussed is TTR; the disease is primary systemic amyloidosis.